12,372 trials
Major Depressive Disorder
Primary: Change From Baseline to End of Treatment (Week 6) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score — -4.8; -4.6 units on a scale — p=0.782
Pseudomonas Aeruginosa Infection
Primary: Pulmonary Function Test: Forced Expiratory Volume in 1 Second (FEV1) — 0.47; 1.67 Percent (%) change
Hepatitis C Virus
Primary: Percentage of Participants Who Achieved Sustained Virologic Response (SVR12) at Follow-Up Week 12 — 91.7; 89.7 Percentage of participants
Parkinson's Disease Psychosis
Primary: Safety: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs) — 180 Participants
Knee Osteoarthritis
Primary: the Change of Total Sum of K-WOMAC(Korean The Western Ontario and McMaster Universities Arthritis Index) — 51.64; 54.57; 49.94; 30.68 score on a scale
Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Primary: Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3 — 53.7; 54.2; 52.6; 63.1 ETDRS letters — p=<0.001
Diabetic Macular Edema
Primary: Mean Change in "Best-corrected Visual Acuity" at Month 12 — 76.44; 73.09 Letters — p=0.5
Cervical Cancer
Primary: Overall Survival — 21.9; 19.5 months — p=0.125
T Acute Lymphoblastic Leukemia · T Lymphoblastic Lymphoma
Primary: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV) — 89.01; 90.53; 78.07; 86.46 percent probability
Type 1 Diabetes Mellitus
Primary: Change From Baseline in HbA1c to Month 6 — -0.399; -0.402 Percentage of HbA1c — p=0.965
Colorectal Cancer
Primary: Overall Survival (OS) — 8.51; 8.87; 7.10 months — p=0.9871
Psoriasis
Primary: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 in Participants Who Received Risankizumab…
Post-ERCP Pancreatitis
Primary: Number of Participants Who Developed Post-ERCP Pancreatitis — 76; 65 Participants
Generalized Anxiety Disorder · Social Phobia · Separation Anxiety Disorder
Primary: PARS — 11.4; 14.7 units on a scale
Severe Pulmonary Arterial Hypertension
Primary: Serious Adverse Events — 5; 3; 1; 1 participants